Peptide therapeutics will radically extend human longevity
The guest argued that the discovery and production of upstream-regulating peptides will experience an AI-driven boom, leading to major breakthroughs in human healthspan and longevity.
The argument
Peptides (like GLP-1s or the 'Wolverine Stack') act as precise, lighter-touch regulators compared to heavy hormones. The guest expects 50 to 100 new peptides to alter longevity in the next three years as AI accelerates candidate discovery and molecular modeling.
The thesis, stress-tested
✓ What validates it
- ✓FDA approval of new peptide candidates for muscle mass preservation or longevity-related indications
- ✓Phase 3 clinical trial success for Eli Lilly's triple-agonist GLP-1
▸ Risks discussed
- ▸Presence of gray markets and contaminated products
- ▸Potential to extend life without addressing cognitive decline like dementia
- ▸Inadequate societal and healthcare infrastructure to support a rapidly aging population
Hear it yourself
"My strongest prediction is that in the next three years, we will probably discover and produce and create and get into humans another 50 to a 100 peptides that alter our longevity in a meaningful way."
00:00 / 00:14
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE